Strategies to reduce CV risk in RA are modification of traditional risk factors (e.g. lifestyle recommendations, antihypertensive treatment, and cholesterol lowering agents), but accumulating evidence suggest that anti-inflammatory treatment (e.g. with conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) or biological DMARDs (bDMARD, such as TNF-blockers) also reduces CV risk in RA patients [6–9]. This evidence concerns the gene TNF and rheumatoid arthritis.